Defunct Company
Total Trials
3
As Lead Sponsor
As Collaborator
0
Total Enrollment
182
NCT00425178
FGF-1 for Topical Administration for the Treatment of Diabetic or Venous Stasis Ulcers
Phase: Phase 1
Role: Lead Sponsor
Start: Sep 2, 2005
Completion: Dec 1, 2006
NCT00117936
Fibroblast Growth Factor-1 (FGF-1) for the Treatment of Coronary Heart Disease
Phase: Phase 2
Start: Mar 31, 2020
Completion: Mar 31, 2023
NCT00424866
FGF-1 for Intramuscular Injection for the Treatment of Peripheral Arterial Disease
Phase: Phase 1/2
Start: Dec 31, 2020
Completion: Jun 30, 2022